Molecular Mechanism of Cell Signaling Pathways of Cancer Cells in Forward and Reverse Mutation: A Perspective Review

References (52)

1. 1 Targeting RAS–ERK signalling in cancer: promises and challenges [DOI]
2. 2 The role of focal-adhesion kinase in cancer — a new therapeutic opportunity [DOI]
3. 3 Current Challenges in Cancer Treatment [DOI]
4. 4 PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? [DOI]
5. 5 Role of p53 in Cell Death and Human Cancers [DOI]
6. 6 Review of cancer from perspective of molecular [DOI]
7. 7 Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression [DOI]
8. 8 Cell Cycle Regulation by Checkpoints [DOI]
9. 9 Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review [DOI]
10. 10 Intron retention is a widespread mechanism of tumor-suppressor inactivation [DOI]
11. 11 Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview [DOI]
12. 12 Understanding and targeting resistance mechanisms in cancer [DOI]
13. 13 Signaling pathways in cancer metabolism: mechanisms and therapeutic targets [DOI]
14. 14 Can cancer be reversed by engineering the tumor microenvironment? [DOI]
15. 15 Biological models and genes of tumor reversion: Cellular reprogramming through tpt1 /TCTP and SIAH-1 [DOI]
16. 16 The therapeutic significance of mutational signatures from DNA repair deficiency in cancer [DOI]
17. 17 Cancer as a Metabolic Disorder [DOI]
18. 18 Rare, Evolutionarily Unlikely Missense Substitutions in ATM Confer Increased Risk of Breast Cancer [DOI]
19. 19 The molecular programme of tumour reversion: the steps beyond malignant transformation [DOI]
20. 20 Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation [DOI]
21. 21 Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk [DOI]
22. 22 Cancer driver mutations: predictions and reality [DOI]
23. 23 Tumor Suppressors Having Oncogenic Functions: The Double Agents [DOI]
24. 24 Genetic Variation and its Role in Malignancy [DOI]
25. 25 The Role and Function of Ras-association domain family in Cancer: A Review [DOI]
26. 26 Targeting BRAF and RAS in Colorectal Cancer [DOI]
27. 27 Gain-of-Function Mutations: An Emerging Advantage for Cancer Biology [DOI]
28. 28 Cell Reversal From a Differentiated to a Stem-Like State at Cancer Initiation [DOI]
29. 29 Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies [DOI]
30. 30 To Investigate the Occurrence and Development of Colorectal Cancer Based on the PI3K/AKT/mTOR Signaling Pathway [DOI]
31. 31 Critical transition and reversion of tumorigenesis [DOI]
32. 32 Human Variation in DNA Repair, Immune Function, and Cancer Risk [DOI]
33. 33 Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1and results in apoptosis and tumor suppression [DOI]
34. 34 Inverse Correlation between Cyclin A1 Hypermethylation and p53 Mutation in Head and Neck Cancer Identified by Reversal of Epigenetic Silencing [DOI]
35. 35 Secondary mutations of BRCA1/2 and drug resistance [DOI]
36. 36 Apoptosis drives cancer cells proliferate and metastasize [DOI]
37. 37 RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally [DOI]
38. 38 Redefining global health priorities: Improving cancer care in developing settings [DOI]
39. 39 mTOR Signaling in Cancer Cell Motility and Tumor Metastasis [DOI]
40. 40 The significance of gene mutations across eight major cancer types [DOI]
41. 41 Inducing stable reversion to achieve cancer control [DOI]
42. 42 Modulation of cancer cell signaling by long noncoding RNAs [DOI]
43. 43 Tumor reversion: a dream or a reality [DOI]
44. 44 Is Cancer Reversible? Rethinking Carcinogenesis Models—A New Epistemological Tool [DOI]
45. 45 Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia [DOI]
46. 46 Cancer reversion, a renewed challenge in systems biology [DOI]
47. 47 Forward and reverse mutations in stages of cancer development [DOI]
48. 48 Mutations and Repair [DOI]
49. 49 BRCA2 reversion mutation confers resistance to olaparib in breast cancer [DOI]
50. 50 Cell Signaling in Cancer [DOI]
51. 51 The phenotypic reversion of cancer: Experimental evidences on cancer reversibility through epigenetic mechanisms (Review) [DOI]
52. 52 Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy [DOI]

Cited by 7

Showing 3 of 7 known citations — external sources report more than can currently be individually listed.

Related research

• Antitumor Activity of Turnera subulata Sm. (Turneraceae) in Hep G2 Cancer Cell Line — shares topic coverage